m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00037)
Name
6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline
Synonyms
CHEMBL419248; 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline; ZINC13737710
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H17NO3
InChI
1S/C18H17NO3/c1-20-16-7-5-4-6-14(16)13-8-12-9-17(21-2)18(22-3)10-15(12)19-11-13/h4-11H,1-3H3
InChIKey
ZGHJQSABDREYEE-UHFFFAOYSA-N
PubChem CID
10085862
TTD Drug ID
D05EDW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Platelet-derived growth factor receptor alpha (PDGFRA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). [1], [2]
References
Ref 1 METTL3-mediated N (6)-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. 2022 Jan 1;12(1):277-289. doi: 10.7150/thno.63441. eCollection 2022.
Ref 2 A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. doi: 10.1021/jm00040a003.